Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to ...

On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, ...

Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences ...

Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop tomorrows genetic therapies.

EmVenio is a global leader in clinical research, dedicated to advancing medical breakthroughs by making studies more accessible and inclusive. We believe that delivering meaningful results begins with ...

On the Business of Biotech this week, Sahir Ali, Ph.D., founder and general partner at Modi Ventures, a family office investing at the intersection of technology and biology, talks about adapting the ...

The Sartocheck® 5 Plus perfectly meets today’s key industry requirements for filter integrity testing in demanding GMP environments. By combining a unique approach to Quality Risk Management, with ...

A conversation with Amanda Howley, Director of Services Solutions at Suvoda The World Medical Association (WMA) has announced a significant, rare update to its cornerstone ethical document, the ...

Suvoda is a global clinical trial technology company whose real-time experience platform empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action.

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...

Decades of technological innovation and scientific advances have revolutionized the treatment paradigm for many conditions that have long eluded conventional therapies. Advanced viral vector-based ...

Oncolytic viruses (OVs) are natural or recombinant attenuated versions of common viruses that do not cause disease but instead infect tumor cells preferentially over healthy cells. The virus ...